These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3178 related articles for article (PubMed ID: 19900250)

  • 21. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multinational trials-recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force report.
    Wild D; Eremenco S; Mear I; Martin M; Houchin C; Gawlicki M; Hareendran A; Wiklund I; Chong LY; von Maltzahn R; Cohen L; Molsen E
    Value Health; 2009 Jun; 12(4):430-40. PubMed ID: 19138309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
    Berger ML; Mamdani M; Atkins D; Johnson ML
    Value Health; 2009; 12(8):1044-52. PubMed ID: 19793072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection of and Evidentiary Considerations for Wearable Devices and Their Measurements for Use in Regulatory Decision Making: Recommendations from the ePRO Consortium.
    Byrom B; Watson C; Doll H; Coons SJ; Eremenco S; Ballinger R; Mc Carthy M; Crescioni M; O'Donohoe P; Howry C;
    Value Health; 2018 Jun; 21(6):631-639. PubMed ID: 29909867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the Comparability of Paper and Electronic Versions of the EORTC QOL Module for Head and Neck Cancer: A Qualitative Study.
    Norquist J; Chirovsky D; Munshi T; Tolley C; Panter C; Gater A
    JMIR Cancer; 2017 May; 3(1):e7. PubMed ID: 28500019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conscious sedation guidance.
    Coulthard P
    Evid Based Dent; 2006; 7(4):90-1. PubMed ID: 17187034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.
    Wild D; Grove A; Martin M; Eremenco S; McElroy S; Verjee-Lorenz A; Erikson P;
    Value Health; 2005; 8(2):94-104. PubMed ID: 15804318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.
    Goswami P; Oliva EN; Ionova T; Else R; Kell J; Fielding AK; Jennings DM; Karakantza M; Al-Ismail S; Lyness J; Collins GP; McConnell S; Langton C; Al-Obaidi MJ; Oblak M; Salek S
    J Comp Eff Res; 2019 May; 8(7):523-533. PubMed ID: 31037971
    [No Abstract]   [Full Text] [Related]  

  • 34. Translation and psychometric properties of the Persian version of self-management of type 1 diabetes for adolescents.
    Karahroudy FA; Shahboulaghi FM; Hosseini MA; Rassouli M; Biglarian A
    J Pediatr Endocrinol Metab; 2016 Jul; 29(7):761-7. PubMed ID: 27124671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
    Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
    Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument.
    Patrick DL; Burke LB; Gwaltney CJ; Leidy NK; Martin ML; Molsen E; Ring L
    Value Health; 2011 Dec; 14(8):967-77. PubMed ID: 22152165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument.
    McCarrier KP; Atkinson TM; DeBusk KP; Liepa AM; Scanlon M; Coons SJ;
    Clin Ther; 2016 Apr; 38(4):794-810. PubMed ID: 27041408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of electronic patient-reported outcome assessment with cancer patients in the hospital and at home.
    Wintner LM; Giesinger JM; Zabernigg A; Rumpold G; Sztankay M; Oberguggenberger AS; Gamper EM; Holzner B
    BMC Med Inform Decis Mak; 2015 Dec; 15():110. PubMed ID: 26699708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 159.